Fexinidazole is a novel oral treatment for Trypanosoma brucei gambiense human African trypanoso-2 miasis: g-HAT. Fexinidazole is also active against other kinetoplastid parasites, notably T. cruzi 3 the causative agent of Chagas disease.During the course of a dose ranging assessment in chronic in-4 determinate Chagas disease, delayed neutropenia and significant increases in hepatic transaminases 5 were observed and clinical investigations were suspended. We retrospectively analyzed all available 6 pharmacokinetic and pharmacodynamic data on fexinidazole in normal healthy volunteers and in 7 patients with chronic Chagas disease and g-HAT, in order to assess the determinants of toxicity. 8 A population pharmacokinetic model was fitted to plasma concentration data on the bioactive 9 fexinidazole sulfone metabolite from three phase 1 studies, two g-HAT phase 2/3 field trials and one 10 Chagas phase 2 field trial (462 individuals in total). Bayesian exposure-response models were then 11 fitted to hematological and liver related pharmacodynamic outcomes in chronic Chagas patients. 12 Neutropenia, reductions in platelet counts, and elevations in liver transaminases were all found 13 to be exposure and thus dose dependent in patients with chronic Chagas disease. Clinically insignif-14 icant transient reductions in neutrophil and platelet counts consistent with these exposure-response 15 relationships were observed in the g-HAT trials. In contrast, no evidence of hepatotoxicity was 16 observed in the g-HAT trials. 17 Fexinidazole treatment results in a dose dependent liver toxicity and transient bone marrow 18 suppression in Chagas disease. Regimens of shorter duration should be trialled for Chagas. The 19 currently recommended regimen for sleeping sickness provides exposures within a satisfactory safety 20 margin for bone marrow suppression and does not cause hepatotoxicity. 21 1 Abbreviations 22 ALT alanine aminotransferase 23 AST aspartate aminotransferase 24 AUlogC area under the log plasma concentration time curve 25 CNS central nervous system 26 CSF cerebrospinal fluid 27 DBS dry blood spot 28 g -HAT Trypanosoma brucei gambiense human African trypanosomiasis 29 M2 fexinidazole sulfone metabolite 30 NECT Nifurtimox-Eflornithine combination therapy 31 NHV normal healthy volunteers 32 OVL overlapping coefficient 33 PK-PD pharmacokinetics-pharmacodynamics 34 Introduction 35
: Summary of the available pharmacokinetic data. These relate only to the quantification of the metabolite M2. The phase 1 data were used to evaluate the best structural model, and the full dataset was used in the pharmacokinetic analyses in order to estimate the drug exposures in fexinidazole treated chronic Chagas patients and fexinidazole treated g-HAT patients. elevations of ALT and AST were observed between 50 and 100 days after the start of treatment. 80 For the patients whose levels rose above 3 times the ULN (for males: 53 and 46 units/L for ALT and AST. The left column gives the relationship between fitted M2 AUlogC values and peak observed transaminase concentrations (y-axis is on the log 10 scale). The right column gives the relationship between fitted sulfone metabolite (M2) AUlogC values and peak observed fold changes from baseline (y-axis is on the log 2 scale). Individual data points are shown by the blue dots, sigmoid model mean fits along with 90% posterior prediction intervals are shown in red, and the range of AUlogC exposures with the g-HAT regimen is shown by vertical green lines. In the right column, the dashed black line shows the threshold value of 3 x baseline. when the PD outcome is measured both as absolute peak increases (Fig 6, left column) or as relative 140 fold increases (Fig 6, right column the absolute and relative models are above g-HAT exposures ( Table 2) . However for the reductions 147 in platelet counts, the absolute model suggests an EC 50 within the g-HAT exposures ( Table 2) . 
